Source Humanized ATC code none ChemSpider none | Target EpCAM CAS Number 945228-48-8 | |
Type Single-chain variable fragment | ||
Oportuzumab monatox (proposed INN), trade name "Vicinium" is an antineoplastic. Chemically, oportuzumab it is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). The drug is produced by Viventia Bio <http://www.viventia.com, a Canadian company with laboratories in Winnipeg, Canada and headquarters in Philadelphia, Pennsylvania, USA. Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).
Vicinium has been evaluated in phase I and II clinical trials in patients with non-muscle invasive bladder cancer. In these studies, treatment was associated with clinical benefit.
References
Oportuzumab monatox Wikipedia(Text) CC BY-SA